Journal of Oncological Sciences最新文献

筛选
英文 中文
Investigation of a Glioblastoma Risk-Associated SNP of the PTPRB Gene in Familial Glioblastoma 家族性胶质母细胞瘤PTPRB基因SNP与胶质母细胞瘤风险相关的研究
Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2022-93852
H. Nalkiran, Sema Yılmaz Rakıcı, Ihsan Nalkiran
{"title":"Investigation of a Glioblastoma Risk-Associated SNP of the PTPRB Gene in Familial Glioblastoma","authors":"H. Nalkiran, Sema Yılmaz Rakıcı, Ihsan Nalkiran","doi":"10.37047/jos.2022-93852","DOIUrl":"https://doi.org/10.37047/jos.2022-93852","url":null,"abstract":"","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69823922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Nasal Lobular Capillary Hemangioma with Sunitib 舒尼替尼治疗鼻小叶毛细血管瘤
Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2023-96095
A. Alkan, Bilge Can Uyar, Ece Dilan Bozkurt, Resmiye Irmak Yüzügüldü, E. Özgür, Sait Ki̇tapli, Özgür Tanrıverdi
{"title":"Management of Nasal Lobular Capillary Hemangioma with Sunitib","authors":"A. Alkan, Bilge Can Uyar, Ece Dilan Bozkurt, Resmiye Irmak Yüzügüldü, E. Özgür, Sait Ki̇tapli, Özgür Tanrıverdi","doi":"10.37047/jos.2023-96095","DOIUrl":"https://doi.org/10.37047/jos.2023-96095","url":null,"abstract":"ABS TRACT Lobular capillary hemangioma (LCH) or pyogenic granuloma is a rare benign lesion originating from the nasal cavity. We pre-sent a case of nasal LCH successfully palliated with sunitinib. A 65-year-old male patient was hospitalized because of swelling and hyper-emia in the periorbital region for 3 months. A month before admission, episodic epistaxis occurred. Magnetic resonance imaging showed a 35×62×63-mm solid mass filling the right half of the nasal cavity. The biopsy showed LCH, and the patient was diagnosed with metastatic renal cell carcinoma (RCC). The tumor board discussed a strategy that can primarily treat metastatic RCC and symptomatic palliation of LCH. Moreover, sunitinib treatment provided palliation of symptoms related to nasal LCH. He reported that swelling, pain, and epistaxis disappeared during the treatment.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69824695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Impact of Adjuvant Chemotherapy in Patients with Medically Inoperable Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy 辅助化疗对医学上不能手术的非小细胞肺癌患者行立体定向放射治疗的影响
Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2023-95681
Ayşe Kötek Sedef, T. Berber, Özge Kandemir Gürsel, Necla Gürdal, Berna Akkus Yildirim
{"title":"Impact of Adjuvant Chemotherapy in Patients with Medically Inoperable Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy","authors":"Ayşe Kötek Sedef, T. Berber, Özge Kandemir Gürsel, Necla Gürdal, Berna Akkus Yildirim","doi":"10.37047/jos.2023-95681","DOIUrl":"https://doi.org/10.37047/jos.2023-95681","url":null,"abstract":"","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69824719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and Radiological Features and Treatment of Pulmonary Toxicity Associated with Using Immune Checkpoint Inhibitors in Cancer Treatment: A Single-Center Experience 在癌症治疗中使用免疫检查点抑制剂与肺毒性相关的临床和放射学特征和治疗:单中心经验
Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2023-95972
İ. Gökmen, A. Gökyer, Fahri Akgül, Erkan Özcan, A. Alkan, N. Demir, I. Çiçin
{"title":"Clinical and Radiological Features and Treatment of Pulmonary Toxicity Associated with Using Immune Checkpoint Inhibitors in Cancer Treatment: A Single-Center Experience","authors":"İ. Gökmen, A. Gökyer, Fahri Akgül, Erkan Özcan, A. Alkan, N. Demir, I. Çiçin","doi":"10.37047/jos.2023-95972","DOIUrl":"https://doi.org/10.37047/jos.2023-95972","url":null,"abstract":"ABS TRACT Objective: Immune checkpoint inhibitor-related pneumonitis (ICI-P), as a rare, immune-related adverse event, is difficult to diagnose and treat for clinicians because of its life-threatening adverse events and nonspecific clinical and laboratory findings. Material and Methods: Patients with newly developed pulmonary infiltrates receiving ICI for cancer treatment were included in this study, and their images were re-evaluated by a radiologist. Results: In this study, 32 (88.9%) male and four (11.3%) female patients with a median age of 62 years (range: 20-70 years) were enrolled, of whom 26 patients (72.3%) were diagnosed with non-small cell lung cancer. The most frequent ICI-P-related symptom was cough (63.9%). The median time to the occurrence of ICI-P was 3.5 months (range: 0.3-20 months), and the median number of cycles was four (range: 1-25). Ten patients needed hospitalization, 13 patients were found with permanent termination of ICI therapy, and ICI-P recurred in six patients (16.7%). Other immunosuppressive treatments, such as using mycophenolate mofetil and infliximab, were required in three steroid-refractory patients. No patient died due to uncontrolled ICI-P. Conclusion: In our study, consolidation was the most common radiological finding of ICI-P, which may involve the contralateral side as well as the tumor margin, possibly mimicking lymphangitic spread. Although ICI-P diagnosis is based on the exclusion of other differential diagnoses, it can mimic many other clinical conditions. Empirical use of steroids should not be avoided if there is clinical suspicion because of the risk of mortality.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"49 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69824786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gamma-Glutamyl Transferase/Albumin Ratio and Alkaline Phosphatase/Albumin Ratio as Novel Prognostic Markers for Metastatic Pancreatic Cancer γ -谷氨酰转移酶/白蛋白比值和碱性磷酸酶/白蛋白比值作为转移性胰腺癌新的预后指标
Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2022-94940
Elif YÜCE, Evren FİDAN
{"title":"Gamma-Glutamyl Transferase/Albumin Ratio and Alkaline Phosphatase/Albumin Ratio as Novel Prognostic Markers for Metastatic Pancreatic Cancer","authors":"Elif YÜCE, Evren FİDAN","doi":"10.37047/jos.2022-94940","DOIUrl":"https://doi.org/10.37047/jos.2022-94940","url":null,"abstract":"ABS TRACT Objective: Metastatic pancreatic cancer is a common condition and highly lethal condition, emphasizing the urgent need for novel prognostic markers. This study investigated the effect of the gamma-glutamyl transferase/albumin ratio (GAR) and alkaline phosphatase/albumin ratio (APAR) on prognosis. Material and Methods: We conducted a retrospective examination 287 patients diagnosed with metastatic pancreatic cancer between January 2008 2019. Results: The median age was 65 years, and obstructive jaundice was present in 58 (20.2%). Median overall-surviva (OS) was significantly longer in patients without jaundice (6.0 vs. 3.0 months, p=0.005). Furthermore, median OS and progression-free survival (PFS) were extended in the low-GAR-group (6.0 vs. 4.0 months, p=0.001; 5.0 vs. 3.0 months, p<0.01, respectively). Similarly, patients in the low APAR group exhibited longer median OS and PFS (6.0 vs. 3.0 months, p<0.01; 5.0 vs. 3.0 months, p<0.01, respectively). The low neutrophil-to-lymphocyte-ratio (NLR) group demonstrated prolonged median OS and PFS (8.0 vs. 3.0 months, p<0.01; 6.0 vs. 3.0 months, p<0.01, respectively). Additionally, patients in the high prognostic-nutritional-index (PNI) group experienced extended median OS and PFS (6.0 vs. 3.0 months, p<0.01; 5.0 vs. 2.0 months, p=0.02, respectively). Furthermore, members of the low-GAR-group were significantly more prevalent in the low-NLR and low platelet-to-lymphocyte-ratio-groups (79.4% vs. 20.6%, p=0.02 and 75.9% vs. 24.1%, p=0.04, respectively). By contrast, the low-APAR-group had significantly more members than the high-PNI-group (90% vs. 10%, p<0.01). Conclusion: In metastatic pancreatic cancer, both OS and PFS significantly extend in the low-GAR, APAR, and NLR groups, while the high-PNI-group also exhibits enhanced OS and PFS. These findings must be supported by further studies .","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134887735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Resectable Colon Cancer 抗表皮生长因子受体单克隆抗体治疗可切除结肠癌的疗效
Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2023-95963
Yakup ERGÜN
{"title":"Efficacy of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Resectable Colon Cancer","authors":"Yakup ERGÜN","doi":"10.37047/jos.2023-95963","DOIUrl":"https://doi.org/10.37047/jos.2023-95963","url":null,"abstract":"of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) has been proved in the treatment of left-sided RAS wild-type unresectable metastatic colorectal cancer. However, their effectiveness in the early stages of the disease has been questioned. Previous studies have shown that the use of these drugs in an adjuvant setting was not effective and recent evidence suggests that they are also ineffective in patients with resectable liver metastases. Neoadjuvant therapy is currently the standard of care for many types of cancer, and studies in this field are ongoing. There is limited data available on the efficacy of anti-EGFR MoAbs in the treatment of locally advanced colon cancer, and a recent study showed no benefit. This review focused on the perioperative use of anti-EGFR MoAbs in the treat-ment of resectable colon cancer and explored possible explanations for their low effectiveness.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134887741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lorlatinib-Related Vision Loss: Two Cases of Non-Small Cell Lung Cancer with Blindness 氯拉替尼相关性视力丧失:2例非小细胞肺癌伴失明
Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2022-92714
S. Karakaya, Özgen Ahmet Yıldırım, Şeyma Işik, Ş. Yücel, I. Karadag
{"title":"Lorlatinib-Related Vision Loss: Two Cases of Non-Small Cell Lung Cancer with Blindness","authors":"S. Karakaya, Özgen Ahmet Yıldırım, Şeyma Işik, Ş. Yücel, I. Karadag","doi":"10.37047/jos.2022-92714","DOIUrl":"https://doi.org/10.37047/jos.2022-92714","url":null,"abstract":"","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69824039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Effectiveness of Current First-Line Treatments and Evaluation of Prognostic Factors Related to Survival in Castration-Resistant Prostate Cancer with Isolated Bone Metastasis 目前一线治疗对去势抵抗性前列腺癌孤立性骨转移的疗效及预后相关因素的评估
Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2023-95447
Z. Urakçı, S. Ebinç, Z. Oruç, M. Kaplan, M. Küçüköner, A. Işıkdoğan
{"title":"Effectiveness of Current First-Line Treatments and Evaluation of Prognostic Factors Related to Survival in Castration-Resistant Prostate Cancer with Isolated Bone Metastasis","authors":"Z. Urakçı, S. Ebinç, Z. Oruç, M. Kaplan, M. Küçüköner, A. Işıkdoğan","doi":"10.37047/jos.2023-95447","DOIUrl":"https://doi.org/10.37047/jos.2023-95447","url":null,"abstract":"","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69824668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Initial Albumin-Bilirubin Grade as a Prognostic Indicator of Pancreatic Cancer with Liver Metastasis 初始白蛋白-胆红素分级作为胰腺癌肝转移的预后指标
Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2021-87242
S. Ay, M. Atçı, R. Arıkan, Ö. Dülgar, D. Tataroğlu Özyükseler, M. Gümüş
{"title":"Initial Albumin-Bilirubin Grade as a Prognostic Indicator of Pancreatic Cancer with Liver Metastasis","authors":"S. Ay, M. Atçı, R. Arıkan, Ö. Dülgar, D. Tataroğlu Özyükseler, M. Gümüş","doi":"10.37047/jos.2021-87242","DOIUrl":"https://doi.org/10.37047/jos.2021-87242","url":null,"abstract":"","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69821631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic Nutritional Index Predicts Overall Survival Better than Geriatric Nutritional Risk Index in Patients with Metastatic Gastric Cancer 预后营养指数比老年营养风险指数更能预测转移性胃癌患者的总生存期
Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2023-96450
Sümeyye Teki̇n, A. Tatlı, Sema Sezgin Göksu, H. Coşkun
{"title":"Prognostic Nutritional Index Predicts Overall Survival Better than Geriatric Nutritional Risk Index in Patients with Metastatic Gastric Cancer","authors":"Sümeyye Teki̇n, A. Tatlı, Sema Sezgin Göksu, H. Coşkun","doi":"10.37047/jos.2023-96450","DOIUrl":"https://doi.org/10.37047/jos.2023-96450","url":null,"abstract":"seen in patients with gastrointestinal system cancer; affects prognosis, quality of life, and survival. In this study, the prognostic value of the Prognostic Nutritional Index (PNI) and Geriatric Nutritional Risk Index (GNRI) based on malnutrition and systemic inflammatory response were compared to determine which index was more predictive for survival. Material and Methods: A total of 124 patients were included in the study. Statistical analysis was done with SPSS program. Kaplan-Meier analysis and Log-Rank test were used for survival analysis. Factors affecting overall survival (OS) were analyzed with univariate and multivariate Cox regression analysis. The values of the indices in predicting the cutoff point and OS were recorded by calculating area under the curve by receiver operating characteristic analysis. Results: In univariate analysis; primary tumor location at the cardioesophageal junction, increased CRP, decreased lymphocyte count, and low PNI ( ≤ 44.05) significantly decreased OS (p<0.05). Only the primary tumor location at the car-dioesophageal junction was an independent prognostic factor for mortality (hazard ratio: 2.717; 95% confidence interval: 1.292-5.711; p=0.008). Conclusion: Although PNI is not an independent risk factor for OS in patients with metastatic gastric cancer, it can be an indicator of survival. In addition, PNI was found to be a better prognostic marker in predicting OS than GNRI.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69825488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信